Psilocybin for treating substance use disorders?-Reference-Cited by-同舟云学术

Psilocybin for treating substance use disorders?

Published:2016-08-12 Issue:2 Volume:17 Page:203-212
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

de Veen Bas T.H.¹,Schellekens Arnt F.A.²,Verheij Michel M.M.¹,Homberg Judith R.¹

Affiliation:

1. Donders Institute for Brain, Cognition, and Behaviour, Centre for Neuroscience, Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands

2. Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Clinical Neurology,General Neuroscience

Link

https://tandfonline.com/doi/pdf/10.1080/14737175.2016.1220834

Reference102 articles.

1. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010

2. Drug Abuse as Self-Medication for Depression: An Empirical Study

3. Rapid relapse generally follows treatment for substance use disorders among adolescents

4. Diagnostic and Statistical Manual of Mental Disorders

5. Drug addiction: the neurobiology of behaviour gone awry

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov;Translational Psychiatry;2024-07-31

2. Scoping review of the role of equine assisted psychotherapy and learning in opioid abuse treatment;Journal of Veterinary Behavior;2024-07

3. Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders;International Journal of Molecular Sciences;2024-06-13

4. Natural products as the therapeutic strategies for addiction;Biomedicine & Pharmacotherapy;2024-06

5. Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder;Expert Opinion on Emerging Drugs;2024-04-18